# Junta clínica — PT-pseudo_938ba8a478e6 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_938ba8a478e6",
  "pid": "PT-pseudo_938ba8a478e6",
  "task": 1,
  "psa": 7.9,
  "age": 65,
  "months": 1,
  "pirads": "4",
  "psad": 0.07,
  "psav": 2.6,
  "psap": 5.6,
  "vol": 123.0,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.76090467,
  "medhx": "Hypertension, COPD, Chronic kidney disease",
  "meds": "amlodipine, valsartan, metoprolol, tiotropium, salbutamol PRN",
  "notes": "PSA 7.9 ng/mL. PI-RADS 4. PSAD 0.07. Prostate volume 123 mL. csPCa 0.76.",
  "pmhx": [
    "Hypertension",
    "COPD",
    "Chronic kidney disease"
  ],
  "allergies": [],
  "vitals": {
    "weight": "78 kg",
    "height": "180 cm",
    "bmi": "24.1",
    "bp": "123/70 mmHg",
    "hr": "83 bpm",
    "smoking": "Non-smoker",
    "last_dental": "6 mo ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "16 Jan 2025",
  "enc_ref": "Dr. M. Jansen (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Clinician review requested due to escalating antigen levels alongside a previously confirmed malignant biopsy."
    },
    {
      "s": "History",
      "t": "Aged 65 and employed as an office administrator, the individual resides solo, with his nephew designated as next of kin. A married non-smoker, his initial workup commenced in late 2022 following an elevated antigen reading. Chronic conditions include hypertension, chronic obstructive pulmonary disease, and chronic kidney disease. Current pharmacotherapy encompasses amlodipine, valsartan, metoprolol, tiotropium, and salbutamol administered on an as-needed basis. Lower urinary tract complaints register at 8 on the IPSS scale, yet recreational cycling persists at roughly 30 kilometres three times weekly. Recent outpatient visits to gastroenterology for routine colonoscopy and to endocrinology for thyroid evaluation both returned negative findings. Aside from minor visual deficits necessitating large-print materials, systemic complaints, bone discomfort, and urinary blood are denied. Workplace and domestic environments present no notable stressors. Alcohol consumption remains low at two weekly units. The subject maintains full independence in daily routines. A systematic transrectal ultrasound biopsy performed in early 2023 yielded Gleason 4+3 pathology."
    },
    {
      "s": "Physical examination",
      "t": "DRE — consistency: smooth and firm; symmetry: preserved; nodularity: absent. General inspection reveals clear pulmonary fields and a regular cardiac rhythm aligning with his established cardiovascular baseline. Abdominal palpation demonstrates a soft, non-tender contour devoid of masses or organomegaly."
    }
  ],
  "occupation": "office administrator",
  "marital": "Married",
  "living": "Lives alone",
  "next_of_kin": "Nephew",
  "recent_other": [
    "Gastroenterology — surveillance colonoscopy",
    "Endocrine — thyroid screening"
  ],
  "alcohol": "2 units / week",
  "exercise": "Cycling 3x/week, ~30 km",
  "ipss": "IPSS score: 8/35 (moderate LUTS)",
  "admin": "Visual impairment: large-print correspondence requested.",
  "mri_hospital": "Tergooi MC",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_938ba8a478e6
Task: 1

Encounter: Urology - outpatient on 16 Jan 2025.
Referrer: Dr. M. Jansen (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 65-year-old male
  - PSA: 7.9 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.07 ng/mL²
  - PSA velocity: 2.6 ng/mL/yr
  - Prior PSA: 5.6 ng/mL
  - Prostate volume: 123.0 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.76090467 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, COPD, Chronic kidney disease
  - Problem list / PMHx: Hypertension, COPD, Chronic kidney disease
  - Current medication: amlodipine, valsartan, metoprolol, tiotropium, salbutamol PRN
  - Allergies: NKA
  - Additional notes: PSA 7.9 ng/mL. PI-RADS 4. PSAD 0.07. Prostate volume 123 mL. csPCa 0.76.

Vitals: weight 78 kg, height 180 cm, BMI 24.1, BP 123/70 mmHg, HR 83 bpm. Smoking: Non-smoker.

Chief complaint: Clinician review requested due to escalating antigen levels alongside a previously confirmed malignant biopsy.

History: Aged 65 and employed as an office administrator, the individual resides solo, with his nephew designated as next of kin. A married non-smoker, his initial workup commenced in late 2022 following an elevated antigen reading. Chronic conditions include hypertension, chronic obstructive pulmonary disease, and chronic kidney disease. Current pharmacotherapy encompasses amlodipine, valsartan, metoprolol, tiotropium, and salbutamol administered on an as-needed basis. Lower urinary tract complaints register at 8 on the IPSS scale, yet recreational cycling persists at roughly 30 kilometres three times weekly. Recent outpatient visits to gastroenterology for routine colonoscopy and to endocrinology for thyroid evaluation both returned negative findings. Aside from minor visual deficits necessitating large-print materials, systemic complaints, bone discomfort, and urinary blood are denied. Workplace and domestic environments present no notable stressors. Alcohol consumption remains low at two weekly units. The subject maintains full independence in daily routines. A systematic transrectal ultrasound biopsy performed in early 2023 yielded Gleason 4+3 pathology.

Physical examination: DRE — consistency: smooth and firm; symmetry: preserved; nodularity: absent. General inspection reveals clear pulmonary fields and a regular cardiac rhythm aligning with his established cardiovascular baseline. Abdominal palpation demonstrates a soft, non-tender contour devoid of masses or organomegaly.

Patient info: office administrator; Married; Lives alone.
Next of kin: Nephew.

Lifestyle: alcohol 2 units / week; exercise Cycling 3x/week, ~30 km; IPSS score: 8/35 (moderate LUTS).

Recent other appointments: Gastroenterology — surveillance colonoscopy; Endocrine — thyroid screening.
Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.55
  uncertainty  +/- 0.11 epistemic (95% band 0.34-0.77); among patients I cannot tell apart the outcome was 0.99 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; the levels are what moved my prediction across the series, not what a urologist would mark)
  decisive   prior biopsy = Positive (43% of my signal; from bx_positive, bx_none)
  important  comorbidity = 3 on the problem list (21% of my signal; from pmhx_hypercholesterolaemia, n_comorbidities)
  noted      age = 65 (2% of my signal; from age) · DRE = Normal (10% of my signal; from dre_suspicious) · PSA = 7.9 ng/mL (3% of my signal; from log_psa, psav) · prostate volume = 123 mL (1% of my signal; from log_vol, vol) · PSA density = 0.07 (0% of my signal; from psad_calc, log_psad) · csPCa probability = 0.76 (1% of my signal; from cspca) · PI-RADS = 4 (20% of my signal; from pirads_ge4, pirads_ge3)
  not used   family history
CONFIDENCE: uncertain — 'discuss' tier; out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

I read 39 raw variables, all from the panel — nothing from the mpMRI prose, the PSA
trajectory, the previous notes or the laboratory. Out-of-fold over 91 labelled cases: AUC
0.758, balanced accuracy 0.625.
The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; 'decisive' marks the variable the rule turns on)
  important  prior biopsy = Positive
  noted      age = 65 · DRE = Normal · PSA = 7.9 ng/mL · prostate volume = 123 mL · PSA density = 0.07 · PI-RADS = 4 · comorbidity = 3 on the problem list
  not used   family history, csPCa probability
CONFIDENCE: uncertain — none of my three panel rules applies; the fact that would settle it — the documented prior grade — lives in the notes, not on the panel

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.94: PI-RADS 4, PSA 6.5, PSAD 0.11, age 64, DRE Normal -> DEFER (uncertain). He wrote: "Need initial ISUP grade and MRI in men on active surveillance."
  2. distance 0.96: PI-RADS 4, PSA 5.3, PSAD 0.092, age 65, DRE Normal -> BIOPSY (clear). He wrote: "P4 in 65 years old patient"
  3. distance 1.12: PI-RADS 4, PSA 8.4, PSAD 0.1, age 63, DRE Normal -> BIOPSY (uncertain). He wrote: "Patient on Active surveillance. Initial ISUP and MRI is needed."

PRECEDENT: BIOPSY (weighted vote 0.65 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

WHAT THE READING UROLOGIST WEIGHED IN THESE PRECEDENTS — in the form's vocabulary, with this man's values (weighted majority of the 3 nearest labelled traces; the distance itself is on PI-RADS, prior biopsy first)
  important  prior biopsy = Positive · age = 65 · PSA = 7.9 ng/mL · PI-RADS = 4
  noted      family history = not opened (0 of 91) · DRE = Normal · prostate volume = 123 mL · PSA density = 0.07
  not used   csPCa probability, comorbidity
CONFIDENCE: uncertain — in this situation the library is no better than chance (47% out of fold)

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 49 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.

WHAT HE WEIGHS — in the form's vocabulary, with this man's values (these are the levels that go on the form, unless a colleague shows a reason to move one)
  important  prior biopsy = Positive · age = 65 · PSA = 7.9 ng/mL · PI-RADS = 4
  noted      family history = not opened (0 of 91) · DRE = Normal · prostate volume = 123 mL · PSA density = 0.07 · comorbidity = 3 on the problem list
  not used   csPCa probability
CONFIDENCE: clear — the level the reading urologist records in this situation, from his labelled traces

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The retrieved guideline discusses using PI-RADS thresholds to guide biopsy decisions, noting that a threshold of PI-RADS $\ge 3$ is used to trigger biopsy, and that increasing the threshold to $\ge 4$ could avoid a significant number of biopsies while missing some cancer.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, I note that the guideline treats the PI-RADS score as a factor in the decision, whereas EXPERT-STRUCTURED marked PI-RADS as decisive, while the guideline suggests a threshold approach. EXPERT-COHORT, the cohort criterion noted that the prior positive biopsy means the panel does not determine the decision, and the guideline requires the documented grade of the prior biopsy to settle the issue. EXPERT-LIBRARY, the precedents suggest a decision based on PI-RADS 4 and PSA levels, which the guideline addresses via risk-adapted matrices.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the documented grade of the prior biopsy: at ISUP 2 or above the guideline sends him to treatment, not to more tissue; if it is unrecorded the indication stands
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - the PSA trajectory: the guideline requires this to be considered in conjunction with other factors to guide the decision
laboratory_results - the laboratory results: the guideline requires PSA density to be considered in conjunction with PI-RADS score

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

The case hinges entirely on the documented grade of the prior biopsy, which is contained within the previous notes, as the panel alone is inconclusive.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Determine whether the lesion is compared against an earlier study.
  psa_trend (get_psa_trend) -> Consider the PSA trajectory in conjunction with other factors to guide the decision.
  previous_notes (get_previous_notes) -> Determine the documented grade of the prior biopsy and whether the patient is on a surveillance protocol with a confirmatory biopsy due.

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the documented grade of the prior biopsy?
  Q2. Does the lesion in the radiology report show change compared to an earlier study?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The lesion is compared against an earlier study: new
LESION
Size and zone of the index lesion, as the report words it: focal zone of restricted diffusion measures 18 x 14 x 16 mm in the right mid-gland peripheral zone.
previous_notes
PRIOR GRADE: not recorded
BIOPSY SESSIONS: 1, performed in early 2023
SURVEILLANCE: not recorded
TREATMENT: none recorded

WHAT I DID NOT OPEN
laboratory_results, family-history anamnesis, psa_trend

WHAT THIS SUPPORTS
FOR sampling this patient now
Prior biopsy was Positive
PSA trend shows an upward trajectory from 2.1 (Dec 2022) to 7.9 (Jan 2025)
MRI shows a PI-RADS 4 lesion localized to the right mid-gland peripheral zone
AGAINST sampling this patient now
Prior biopsy was Positive (as this is a known finding, not new information)
nothing

WHERE THIS LEANS
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 7.90 ng/mL over 4 points spanning 25 months; velocity +2.76 ng/mL per year; doubling time about 13 months.
PROJECTION at 6 months: 11.9 ng/mL, conformal 95% band 3.4-41.3.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (the serial PSA only)
  noted      PSA = 7.9 ng/mL
  not used   prior biopsy, family history, age, DRE, prostate volume, PSA density, csPCa probability, PI-RADS, comorbidity
CONFIDENCE: borderline — the conformal band does not clear the last value

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.54
  uncertainty  +/- 0.10 epistemic (95% band 0.35-0.74), of which 0.01 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 59% of the time over the 29 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel + the documents that were opened; PI-RADS here means the report's own wording — DWI restriction, lesion size — not the score)
  decisive   prior biopsy = Positive (43% of my signal; from bx_positive, bx_none)
  important  PI-RADS = 4 (22% of my signal; from rad_dwi_restriction, rad_lesion_ge15mm)
  noted      PSA = 7.9 ng/mL (21% of my signal; from fpsa_lt15, psa_delta_prev) · prostate volume = 123 mL (4% of my signal; from log_vol, vol) · PSA density = 0.07 (0% of my signal; from psad_calc) · comorbidity = 3 on the problem list (4% of my signal; from n_comorbidities, on_alpha_blocker)
  not used   family history, age, DRE, csPCa probability
CONFIDENCE: uncertain — 'discuss' tier; out-of-fold it was right 59% of the time over the 29 labelled cases in this tier

Out-of-fold AUC 0.794. I am the only expert that has read the report's
wording, and I still cannot see the prior grade or the surveillance history: those are in the notes, and
the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.55  ('discuss' tier; weight 1.0)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.54  ('discuss' tier, fusion_nolab; weight 1.5)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=0.65  (k=3 precedents; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: weighted vote of the trained experts, p = 0.55 — carried by weighted panel.
PANEL ANSWER: BIOPSY. EXPERT-FUSION carried the most weight ('discuss' tier, fusion_nolab). In this bucket no rule applied and the documents did not record the prior grade, so the trained experts decide.

THE BOARD'S VARIABLES — value · what each expert marked · what goes on the form
  bx           Positive                     E1:DEC E3:DEC cohort:IMP library:IMP E2:—            -> important
  fh           not opened (0 of 91)         E1:— E3:— cohort:— library:not E2:—                  -> not_used (raised from noted by the board)
  age          65                           E1:not E3:— cohort:not library:IMP E2:—              -> important
  dre          Normal                       E1:not E3:— cohort:not library:not E2:—              -> not_used (raised from noted by the board)
  psa          7.9 ng/mL                    E1:not E3:not cohort:not library:IMP E2:not          -> important
  vol          123 mL                       E1:not E3:not cohort:not library:not E2:—            -> noted
  psad         0.07                         E1:not E3:not cohort:not library:not E2:—            -> noted
  cspca        0.76                         E1:not E3:— cohort:— library:— E2:—                  -> not_used
  pirads       4                            E1:not E3:IMP cohort:not library:IMP E2:—            -> important
  comorbidity  3 on the problem list        E1:IMP E3:not cohort:not library:— E2:—              -> noted
  (DEC decisive · IMP important · not noted · — not used; the last column is the level recorded, from the trace of the reading urologist)

Confidence to record: borderline.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents the registrar opened (radiology_report, psa_trend, previous_notes) address the moderator's questions. The previous_notes state the prior grade was "not recorded," and the radiology_report states the lesion is "new" compared to an earlier study.

ALIGNMENT WITH THE PANEL
The retrieved evidence, specifically the lack of a documented prior grade in the previous_notes and the finding of a new lesion in the radiology_report, aligns with the PANEL-PROTOCOL's conclusion that the decision rests on the documents, as the protocol noted "documented prior grade in the opened documents: none recorded."

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the documented grade of the prior biopsy? Answered by the previous_notes: "PRIOR GRADE: not recorded." Q2. Does the lesion in the radiology report show change compared to an earlier study? Answered by the radiology_report: "new."

WHAT CARRIES WEIGHT, AND WHY
<prior biopsy>: Positive (noted) because the prior biopsy was positive, which is a known finding not new information. I would move this to 'important' because the prior result is central to the decision, even if not new. <psa>: 7.9 ng/mL (important) because the rising PSA trajectory is noted, which Expert-PSA flagged as borderline. <pirads>: 4 (important) because the PI-RADS score is important, as Expert-STRUCTURED marked it decisive. My confidence in the record as it stands is borderline.

MY SUGGESTION TO THE CHAIR
The panel's decision to BIOPSY is supported by the fact that the prior biopsy was positive and the MRI shows a new lesion, despite the lack of a documented prior grade. I suggest proceeding with a biopsy, leaning towards a more aggressive approach given the rising PSA and PI-RADS 4 finding.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: borderline)

65y male, PSA 7.9, PSAD 0.07, PI-RADS 4, prior biopsy positive but grade not recorded. New lesion noted on MRI warrants sampling to determine management. Low PSAD argues for observation, but the unknown prior grade dictates sampling for definitive risk stratification.

What carried weight: bx=important, age=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes
